Literature DB >> 16950425

Peripheral atherectomy in TransAtlantic InterSociety Consensus type C femoropopliteal lesions for limb salvage.

Andrea E Yancey1, David J Minion, Christian Rodriguez, Donald E Patterson, Eric D Endean.   

Abstract

BACKGROUND: The optimal therapy for TransAtlantic Societal Consensus (TASC) type C femoropopliteal lesions remains a critical issue in the treatment of infrainguinal occlusive disease. The purpose of this study was to evaluate the outcome of limbs with TASC C femoropopliteal lesions and critical limb ischemia treated with the FoxHollow SilverHawk atherectomy catheter.
METHODS: From September 2004 to September 2005, 18 consecutive femoropopliteal procedures performed in 17 limbs in 16 patients were reviewed. Demographic data, baseline angiographic findings, and indications for the procedures were recorded. Clinical outcomes including symptom resolution and limb salvage were determined for the 17 primary procedures. Hemodynamic improvement was compared by using the paired Student t test. Stenosis-free patency was determined by the Kaplan-Meier method.
RESULTS: The mean age was 72.5 years (range, 47-88 years). Fifty percent of the patients had four or more of the following risk factors: hypertension, diabetes, tobacco use, hyperlipidemia, renal insufficiency, and coronary artery disease. The indication was tissue loss in 13 limbs and rest pain in 4. All patients had a second level of disease, either inflow or tibial/pedal, which was treated concurrently when appropriate. Initial resolution of symptoms was achieved in 12 limbs, and partial healing was achieved in 2 others. Early amputation was necessary in the remaining three patients, but this was likely due to severe inframalleolar disease and advanced forefoot ischemia at the time of presentation. Five patients have remained symptom-free without restenosis at a mean follow-up of 6 months. Two patients have required late amputation for hemodynamic failure. The ankle-brachial index improved from 0.39 +/- 0.08 (mean +/- SEM) before surgery to 0.75 +/- 0.08 in the immediate postoperative period (P = .02). However, it returned toward baseline at 6 months after surgery, with a mean of 0.48 +/- 0.07. Stenosis-free patency of the femoropopliteal segment was 22% at 12 months.
CONCLUSIONS: Peripheral atherectomy can achieve good early clinical and hemodynamic success in patients with TASC C lesions and critical limb ischemia. However, mid-term restenosis rates are high in this challenging cohort of patients.

Entities:  

Mesh:

Year:  2006        PMID: 16950425     DOI: 10.1016/j.jvs.2006.05.038

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  5 in total

1.  Shifting paradigms in the treatment of lower extremity vascular disease: a report of 1000 percutaneous interventions.

Authors:  Brian G DeRubertis; Peter L Faries; James F McKinsey; Rabih A Chaer; Matthew Pierce; John Karwowski; Alan Weinberg; Roman Nowygrod; Nicholas J Morrissey; Harry L Bush; K Craig Kent
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

2.  Endovascular management of the popliteal artery: comparison of atherectomy and angioplasty.

Authors:  Elie Semaan; Naomi Hamburg; Wael Nasr; Palma Shaw; Robert Eberhardt; Jonathan Woodson; Gheorghe Doros; Denis Rybin; Alik Farber
Journal:  Vasc Endovascular Surg       Date:  2009-11-25       Impact factor: 1.089

3.  Is atherectomy the best first-line therapy for limb salvage in patients with critical limb ischemia?

Authors:  Gabriel Loor; Christopher L Skelly; Carl-Magnus Wahlgren; Hisham S Bassiouny; Giancarlo Piano; Wael Shaalan; Tina R Desai
Journal:  Vasc Endovascular Surg       Date:  2009-07-29       Impact factor: 1.089

4.  Inferior mesenteric artery stump pressure is an unreliable predictor of the outcome of colorectal anastomosis.

Authors:  Tzu-Chi Hsu
Journal:  Int J Colorectal Dis       Date:  2007-07-18       Impact factor: 2.571

5.  Effective endovascular treatment of calcified femoropopliteal disease with directional atherectomy and distal embolic protection: final results of the DEFINITIVE Ca⁺⁺ trial.

Authors:  David Roberts; Khusrow Niazi; William Miller; Prakash Krishnan; Roger Gammon; Theodore Schreiber; Nicolas W Shammas; Daniel Clair
Journal:  Catheter Cardiovasc Interv       Date:  2014-02-05       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.